Compare BDSX & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDSX | ABEO |
|---|---|---|
| Founded | 2005 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.2M | 399.5M |
| IPO Year | 2020 | 2005 |
| Metric | BDSX | ABEO |
|---|---|---|
| Price | $26.63 | $5.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $32.50 | $20.00 |
| AVG Volume (30 Days) | 122.8K | ★ 1.5M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $88,499,000.00 | $2,998,000.00 |
| Revenue This Year | $25.26 | $1,024.31 |
| Revenue Next Year | $19.15 | $145.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 24.08 | ★ 258.18 |
| 52 Week Low | $0.35 | $4.00 |
| 52 Week High | $31.31 | $7.65 |
| Indicator | BDSX | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 42.98 |
| Support Level | $19.26 | $5.71 |
| Resistance Level | $31.31 | $5.97 |
| Average True Range (ATR) | 2.56 | 0.18 |
| MACD | -0.18 | -0.02 |
| Stochastic Oscillator | 51.91 | 29.63 |
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.